Are cancer stem cells radioresistant?

Future Oncology

Volumn 6, Issue 10, 2010, Pages 1563-1576

  Hittelman, Walter N ^a   Liao, Yong ^a   Wang, Li ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cancer cell clonogen; cancer stem like cell; cancer stem like cell dynamics; radioresistance determinant; therapeutic strategy

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE REGULATION; CELL SURVIVAL; DNA REPAIR; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW;

ANIMALS; HUMANS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE;

EID: 78149443146     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.121     Document Type: Review

References (106)

1. Redmond KM, Wilson TR, Johnston PG et al.: Resistance mechanisms to cancer chemotherapy. Front. Biosci. 13, 5138-5154 (2008).
2. 95 radiation dose. Nature 211 (5052), 996-997 (1966).
3. Ando K, Koike S, Shikita M et al.: Radiosensitivity of late recurrences following radiotherapy of murine fbrosarcomas. Radiat. Res. 113 (2), 334-345 (1988).
4. Hall EJ: Radiobiology for the Radiologist (5th Edition). Lippincott Williams & Wilkins, NY, USA (2000).
5. Milas L, Hittelman WN: Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin. Radiat. Oncol. 19(2), 96-105 (2009).
6. Shelby P, Buick RN, Tannock I: A critical appraisal of the "human tumor stem-cell assay". N. Engl. J. Med. 308(3), 129-134 (1983).
7. Buick RN: Radiological and clinical implications of the stem cell concept in human malignancy. In: Cancer Biology and Therapeutics. Cory JG, Szentivany A (Eds). Plenum Publishers, NY, USA, 65-76 (1987).
8. Hill RP, Milas L: The proportion of stem cells in murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 16(2), 513-518 (1989).
9. Peters LJ, Hewitt H: The infuence of fbrin formation on the transplantability of murine tumor cells: implications for the mechanism of the Revesz effect. Br. J. Cancer 29(4), 279-291 (1974).
10. Milas L, Ito H, Hunter N et al.: Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: dependency on tumor type. Cancer Res. 46(2), 712-727 (1986).
11. Milas L, Peters LJ: Conditioning of tissues for metastasis formation by radiation and cytotoxic drugs. In: Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. Nicholson GL, Milas L (Eds). Raven Press, NY, USA, 321-336 (1984).
12. Bickenbach JR, Chism E: Selection and extended growth of murine epidermal stem cells in culture. Exp. Cell Res. 244(1), 184-195 (1998).
13. Goodell MA, Brose K, Paradis G et al.: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183(4), 1797-1806 (1996).
14. Al-Hajj M, Wicha MS, Benito-Hernandez A et al.: Prospective identifcation of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003). (Pubitemid 36418143)
15. Jordan CT: Cancer stem cell biology: from leukemia to solid tumors. Curr. Opin. Cell Biol. 16(6), 708-712 (2004).
16. Wang JC, Dick JE: Cancer stems cells: lessons from leukemia. Trends Cell Biol. 15(9), 494-501 (2005).
17. O'Brien CA, Kreso A, Dick JE: Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 19(2), 71-77 (2009).
18. Singh SK, Clarke ID, Terasaki M et al.: Identifcation of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003).
19. Hammati HD, Nakano I, Lazareff JA et al.: Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100(25), 5178-15183 (2003).
20. Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 66(4), 1883-1890 (2006).
21. Hill RP: Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66(4), 1891-1896 (2006).
22. Quintana E, Shackleton M, Sabel MS et al.: Effcient tumour formation by single human melanoma cells. Nature 456(7222), 593-598 (2008).
23. Kemper K, Sprick MR, de Bree M et al.: The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 70(2), 719-729 (2010).
24. Cardo-Vila M, Zurita AJ, Giordano RJ et al.: A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS ONE 3(10), E3452 (2008).
25. Shackleton M, Quintana E, Fearon ER et al.: Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138(5), 822-829 (2009).
26. Mani SA, Guo W, Liao MJ et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008).
27. Gupta PB, Chaffer CL, Weinberg RA: Cancer stem cells: mirage or reality? Nat. Med. 15(9), 1010-1012 (2009).
28. Morrison SJ, Spradling AC: Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132(4), 598-611 (2008).
29. Voog J, Jones DL: Stem cells and the niche: a dynamic duo. Cell Stem Cell 6(2), 103-115 (2010).
30. Crosnier C, Stamataki D, Lewis J: Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat. Rev. Genet. 7(5), 349-359 (2006).
31. Williams DA, Cancelas JA: Leukaemia: niche retreats for stem cells. Nature 444(7121), 827-828 (2006).
32. Molofsky AV, Pardal R, Morrison SJ: Diverse mechanisms regulate stem cell self-renewal. Curr. Opin. Cell Biol. 16(6), 700-707 (2004).
33. Henrique D, Hirsinger E, Adam U et al.: Maintenance of neuroepithelial progenitor cells by δ-Notch signaling in the embryonic chick retina. Curr. Biol. 7(9), 661-670 (1997).
34. Battle E, Henderson JT, Beghtel H et al.: β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111(2), 251-263 (2002).
35. Van de Wetering M, Sancho E, Verweij C et al.: The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111(2), 241-250 (2002).
36. Lai K, Kaspar BK, Gage FH et al.: Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci. 6(1), 21-27 (2003).
37. Kai T, Spradling A: An empty Drosophila stem cell niche reactivates the proliferation of ectopic cells. Proc. Natl Acad. Sci. USA 100(8), 4633-4638 (2003).
38. Evangelista M, Tian H, de Sauvage J: The hedgehog signaling pathway in cancer. Clin. Cancer Res. 12(20 Pt 1), 5924-5928 (2006).
39. Bissell MJ, LaBarge MA: Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7(1), 17-23 (2005).
40. Jones DL, Wagers AJ: No place like home: anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell Biol. 9(1), 11-21 (2008).
41. Scadden DT: The stem-cell niche as an entity of action. Nature 441(7097), 1075-1079 (2006).
42. Tannock IF: Tumor physiology and drug resistance. Cancer Metastasis Rev. 20(1-2), 123-132 (2001).
43. Withers HR, Taylor JMG, Maciejewski B: The hazard of accelerated tumors clonogen repopulation during radiotherapy Acta Oncol. 27(2), 131-146 (1988).
44. Milas L, Yamada S, Hunter N et al.: Changes in TCD,., as a measure of clonogen doubling-J{J time in irradiated and unirradiated tumors. Int. J. Radiat. Oncol. Biol. Phys. 21(5), 1195-1202 (1991).
45. Thames HD, Ruifrock AC, Milas L et al.: Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: downregulation of apoptosis as a possible mechanism. Int. J. Radiat. Oncol. Biol. Phys. 35(5), 951-962 (1996).
46. Jaiswal S, Jamieson CHM, Pang WW et al.: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2), 271-285 (2009).
47. Marusyk A, Polyak K: Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805(1), 105-117 (2010).
48. Liao Y, Valdecanas DP, Liu S et al.: Visualizing lung tumor heterogeneity by color-coding clonal cell subpopulations. Presented at: 101st American Association for Cancer Research Annual Meeting. Washington, DC, USA, 17-21 April 2010.
49. Baumann M, Krause M, Hill R: Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8(7), 545-554 (2008).
50. Ishii H, Iwatsuki M, Ieta K et al.: Cancer stem cells and chemoradiation resistance. Cancer Sci. 99(10), 1871-1877 (2008).
51. Woodward WA, Bristow RG: Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin. Radiat. Oncol. 19(2), 87-95 (2009).
52. Pajonk F, Vlashi E, McBride WH: Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28(4), 639-648 (2010).
53. Diehn M, Cho RW, Lobo NA et al.: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239), 780-783 (2009).
54. Bao S, Wu Q, McLendon RE et al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756-760 (2006).
55. Vlashi E, Kim K, Lagadec C et al.: In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl Cancer Inst. 101(5), 350-359 (2009).
56. Pine SR, Ryan BM, Varticovski L et al.: Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc. Natl Acad. Sci. USA 107(5), 2195-2200 (2010).
57. Brown JM: Tumor hypoxia in cancer therapy. Methods Enzymol. 435, 297-321 (2007).
58. Calabrese C, Poppleton H, Kocak M et al.: A perivascular niche for brain tumor stem cells. Cancer Cell 11(1), 69-82 (2007).
59. Cardenas-Navia LI, Mace D, Richardson RA et al.: The pervasive presence of fuctuating oxygenation in tumors. Cancer Res. 68(14), 5812-5819 (2008).
60. Grdina DJ, Milas L, Mason KA, Withers HR: Separation of cells from a fbrosarcoma in renografn density gradients. J. Natl Cancer Inst. 52(1), 253-257 (1974).
61. Grdina DJ, Hittelman WN, White RA et al.: Relevance of density, size and DNA content of tumour cells to the lung colony assay. Br. J. Cancer 36(6), 659-669 (1977).
62. Woodward WA, Chen MS, Behbod F et al.: WNT/±catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA 104(2), 618-623 (2007).
63. Barcellos-Hoff MH, Park C, Wright EG: Radiation and the microenvironment-tumorigenesis and therapy. Nat. Rev. Cancer 5(11), 867-875 (2005).
64. Ghotra VPS, Puigvert JC, Danen EHJ: The cancer stem cell microenvironment and anti-cancer therapy. Int. J. Radiat. Biol. 85(11), 955-962 (2009).
65. Lomonaco SL, Finniss S, Xiang C et al.: The induction of autophagy by γ-radiation contributes to the radioresistance of glioma stem cells. Int. J. Cancer. 125(3), 717-722 (2009).
66. Gupta R, Vyas P, Enver T: Molecular targeting of cancer stem cells. Cell Stem Cell 5(2), 125-126 (2009).
67. Eyler CE, Rich JN: Survival of the fttest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26(17), 2839-2845 (2008).
68. Kim JJ, Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Cancer Rev. 5(7), 516-525 (2005).
69. Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
70. Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase III randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11(1), 21-28 (2010).
71. Hardee ME, Arcasoy MO, Blackwell KL et al.: Erythropoietin biology in cancer. Clin. Cancer Res. 12(2), 332-339 (2006).
72. Phillips TM, Kim K, Vlashi E et al.: Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 9(12), 1122-1129 (2007).
73. Overgaard J, Hoff CM, Hansen HS et al.: Randomized study of darbepoietin α as modifer of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): fnal outcome of the DAHANCA 10 trial. J. Clin. Oncol. 27(155), 15S (2009).
74. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7(9), 987-989 (2001).
75. Winkler F, Kozin SV, Tong RT et al.: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoitin-1, and matrix metalloproteinases. Cancer Cell 6(6), 553-563 (2004).
76. Duda DG, Jain RK, Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25(26), 4033-4042 (2007).
77. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777), 1171-1175 (2006).
78. Ellis LM, Hicklin DJ: Resistance to targeted therapies: refning anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471-7478 (2009).
79. Hayden EC: Cutting off cancer's supply lines. Nature 458(7239), 686-687 (2009).
80. Pennacchietti S, Michieli P, Galluzzo M et al.: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3(4), 347-361 (2003).
81. Saito Y, Uchida N, Tanaka S et al.: Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28(3), 275-280 (2010).
82. Mikkola HKA, Radu CG, Witte ON: Targeting leukemia stem cells. Nat. Biotechnol. 28(3), 237-238 (2010).
83. Estey EH, Thall PF, Pierce S et al.: Randomized Phase II study of fudarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8), 2478-2484 (1999).
84. Hensley ML, Hagerty KL, Kewalramani T et al.: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol. 27(1), 127-145 (2009).
85. Ang KK, Peters LJ, Weber RS et al.: Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 19(6), 1339-1345 (1990).
86. Fu KK, Pajak TF, Trotti A et al.: A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: frst report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 7-16 (2000).
87. Saunders M, Dische S, Barrett A et al.: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicentre trial. Radiother. Oncol. 52(2) 137-148 (1999).
88. Pignon JP, le Maitre A, Bourhis J et al.: Meta-analysis of chemotherapy in head and neck cancer meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update of 93 randomized trials and 17,346 patients. Radiother. Oncol. 92 (1), 4-14 (2009).
89. Mason KA, Hunter NR, Raju U et al.: Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1181-1189 (2004).
90. Raju U, Nakata E, Mason KA et al.: Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res. 63(12), 3263-3267 (2003).
91. Sims-Mourtada J, Izzo JG, Apisarnthanarax S et al.: Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin. Cancer Res. 12(21), 6565-6572 (2006).
92. Revesz L: Effect of lethally damaged tumor cells upon the development of admixed viable cells. J. Natl Cancer Inst. 20(6), 1157-1186 (1958).
93. Hewitt H, Blake E, Porter E: The effect of lethally irradiated cells on the transplantability of murine tumours. Br. J. Cancer 28(2), 123-135 (1973).
94. Milas L, Furuta Y, Hunter N et al.: Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res. 50(15), 4473-4477 (1990).
95. Choy H, Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl Cancer Inst. 95(19), 1440-1452 (2003).
96. Milas L, Fang FM, Mason KA et al.: Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 568-572 (2007).
97. Riesterer O, Mason KA, Raju U et al.: Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. Radiat. Oncol. 92(3), 383-387 (2009).
98. Zips D, Eicheler W, Geyer P et al.: Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res. 65(12), 5374-5379 (2005).
99. Moeller BJ, Dreher MR, Rabbani ZN et al.: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8(2), 99-110 (2005).
100. Ceradini DJ, Kulkarni AR, Callaghan MJ et al.: Progenitor cell traffcking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10(8), 858-864 (2004).
101. Kioi M, Vogel H, Schultz G et al.: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120(3), 694-705 (2010).
102. Shaked Y, Kerbel RS: Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 67(15), 7055-7058 (2007).
103. Yan M, Plowman GD: δ-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 13(24), 7243-7246 (2007).
104. Yan M, Callahan CA, Beyer JC et al.: Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282), E6-E7 (2010).
105. Neelapu SS, Gause BL, Harvey L et al.: A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12), 5160-5163 (2007).
106. Kantoff PW, Schuetz TJ, Blumenstein BA et al.: Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010).